Biological background to aromatase inhibition

Breast

Volumn 5, Issue 3, 1996, Pages 196-201

  Dowsett, M ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; ESTROGEN;

BREAST CANCER; CONFERENCE PAPER; FEMALE; HUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

EID: 0030055053     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(96)90093-4     Document Type: Conference Paper

References (40)

1. Dowsett M. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer. J Steroid Biochem 1990; 37: 1037-1041.
2. Mendelson C R, Wright E E, Evans C T, Porter J C, Simpson E R. Preparation and characterisation of polyclonal and monoclonal antibodies against human aromatase cytochrome P-450 and their use in its purification. Archs Biochem Biophys 1985; 243: 480-491.
3. Chen S, Zhow D, Swiderek K M, Kadohama N, Osawa Y, Hall T F. Structure-function studies of human aromatase. J Steroid Biochem Molec Biol 1993: 44: 347-356.
4. Laughton C A, Zvelevil M J J M, Neidle S. A detailed molecular model for human aromatase. J Steroid Biochem Molec Biol 1993; 44: 399-407.
5. Santen R J, Santner S, Davies B, Veldhuis J, Samojlik E, Ruby B. Aminoglutethimide inhibits extraglandular oestrogen production in postmenopausal women with breast carcinoma. J Clin Endocrinol Metab 1978; 47: 1257-1265.
6. Dowsett M, MacNeill F, Mehta A et al. Endocrine, pharmacokinetical clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl) piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients. Br J Cancer 1991; 64: 887-894.
7. Stein R C, Dowsett M, Davenport J, Hedley A, Coombes R C. Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A. Cancer Res 1990; 50: 1381-1384.
8. Iveson T J, Smith I E, Ahern J, Smithers D A, Truent P, Dowsett M. Phase I study of the oral non-steroidal aromatase inhibitor CGS 20267 in postmenopausal patients with breast cancer. Cancer Res 1993; 53: 266-270.
9. Johnston SRD, Smith I E, Doody D, Jacobs S, Robertshaw H, Dowsett M. The clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 1994; 54: 5875-5881.
10. Yates R A, Dowsett M, Fisher G V, Selen S A, Wyld P J. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in post-menopausal female volunteers. Br J Cancer 1995; In press.
11. Kudoh M, Susk Y, Ideyama Y et al. The potent and selective inhibition of oestrogen production by non-steroidal aromatase inhibitor, YM511. J Steroid Biochem Mol Biol 1995; 54: 265-271.
12. Coombes R C, Hughes SWM, Dowsett M. 4-Hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. Eur J Cancer 1992; 28A: 1941-1945.
13. DiSalle E, Evans TRJ, Ornati G, Zurlo M G, Benedetti M S, Coombes R C. Exemestane, a novel steroidal aromatase inhibitor. Adv in Clin Oncol 1994; 2: 165-171.
14. Brodie A M H, Garrett W, Hendrickson J R, Tsai-Morris C-H, Marcotte P A, Robinson C H. Inactivation of aromatase in vitro by 4-hydroxyandrostenedione and 4-acetoxyandrostenedione and sustained effects in vivo. Steroids 1981; 38: 693-702.
15. Dowsett M, Cunningham D C, Stein R C et al. Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. Cancer Res 1989; 49: 1306-1312.
16. Dowsett M, Goss P E, Powles T J et al. Use of the aromatase inhibitors 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route. Cancer Res 1987; 47: 1957-1961.
17. Hillier S G. Cellular basis of follicular endocrine function. In: Hillier S G, ed. Ovarian Endocrinology, Oxford: Blackwell Scientific, 1991, pp 73-106.
18. Santen R J, Samojlik E, Wells S A. Resistance of the ovary to blockade of aromatization with aminoglutethimide. J Clin Endocrinol Metab 1980; 51: 473-479.
19. Harris A L, Dowsett M, Jeffcoate S L, McKinna J A, Morgan M, Smith I E. Endocrine and therapeutic effects of aminoglutethimide in premenopausal patients with breast cancer. J Clin Endocrinol Metab 1982; 55: 718-722.
20. Wander H E, Blossey HCh, Nagel G A. Aminoglutethimide in the treatment of premenopausal patients with metastatic breast cancer. Eur J Clin Oncol 1986; 22: 1371-1374.
21. Dowsett M, Stein R C, Coombes R C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J Steroid Biochem 1992; 43: 155-159.
22. Stein R C, Dowsett M, Hedley A, Coombes R C. The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. Br J Cancer 1990; 62: 679-683.
23. Wouters W, De Coster R, Tuman R W et al. Aromatase inhibition by R76713: experimental and clinical pharmacology. J Steroid Biochem 1989;34:427-430.
24. De Coster R, Tuman R, Bowden C et al. Endocrine effects of vorozole on pituitary-ovarian function. In: Motta M, Serio M, eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam: Elsevier Science, 1994, pp 287-295.
25. Jacobs S, MacNeill F, Lonnlng P, Dowsett M, Jones A, Powles T J. Aromatase activity, serum oestradiol and their correlation with demographic indices. J Steroid Biochem Molec Biol 1992; 41: 769-771.
26. Hemsell D L, Grodin J M, Brenner P F, Siiteri P T, MacDonald P C. Plasma precursors of oestrogen II. Correlation of extent of conversion of plasma androstenedione to oestrone with age. J Clin Endocrinol Metab 1974; 38: 476-479.
27. Cleland W H, Mendelson C R, Simpson E R. Effects of ageing and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985; 60: 174-177.
28. Simpson E R, Mahendroo M S, Nichols J E, Bulun S E. Regulation of aromatase gene expression: relationship to breast cancer. In: Motta M, Serio M, eds. Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. Amsterdam: Elsevier Science, 1994, pp 269-278.
29. Weisz J, Fritz-Wotz G, Dabbs D, Shelley K, Brodie A, Brown T. Expression of aromatase in epithelial and stromal cells in terminal lobular ductal units and in epithelial cells of cysts in normal human mammary gland. Proc Am Assoc Cancer Res 1995; 36: 273 (Abstr 1631).
30. Miller W R, O'Neill J. The importance of local synthesis of oestrogen within the breast. Steroids 1987; 50: 537-548.
31. Thijssen J H H, Daroszewski J, Milewicz A, Blankenstein M A. Local aromatase activity in human breast tissues. J Steroid Biochem Mol Biol 1993; 44: 577-582.
32. 450 transcripts using polymerase chain reaction. J Clin Endocrinol Metab 1993; 77: 1622-1628.
33. Miller W R, Forrest A P M. Oestradiol synthesis from C19 steroids by human breast cancers. Br J Cancer 1976; 33: 116-118.
34. Lipton A, Santner S J, Santen R J et al. Aromatase activity in primary and metastatic human breast cancer. Cancer 1987; 59: 779-783.
35. Silva M C, Rowlands M G, Dowsett M et al. Intra-tumoural aromatase as a prognostic factor in human breast carcinoma. Cancer Res 1989; 49: 2588-2591.
36. Reed M J, Owen A M, Lai L C et al. In situ oestrone synthesis in normal breast and breast tumour tissues: effect of treatment with 4-hydroxyandrostene. Int J Cancer 1989; 44: 233-237.
37. Bezwoda W R, Manson R, Dansey R. Correlation of breast tumour aromatase activity and response to aromatase inhibition with aminoglutethimide. Oncology 1987; 44: 345-349.
38. Murray R, Pitt P. Aromatase inhibition with 4-OH androstenedione after prior aromatase inhibition with aminoglutethimide in women with associated breast cancer. Breast Cancer Res Treat 1995; 35: 249-253.
39. Dowsett M, Lee K, Macaulay V M, Detre S, Rowlands M, Grimshaw R. The control and biological importance of intratumoural aromatase in breast cancer. J Steroid Biochem Mol Biol 1995; In press.
40. Dowsett M, Harris A L, Smith I E, Jeffcoate S L. Endocrine changes associated with relapse in advanced breast cancer patients on aminoglutethimide therapy. J Clin Endocrinol Metab 1984; 58: 99-104.